



## TriWest Prior Authorization Drug List

Note: No new drugs are being added to the Prior Authorization List effective October 1, 2006. Changes effective October 1, 2006, are listed below.

### *The following drugs will be removed effective October 1, 2006*

<b>Brand Name</b>	<b>Chemical Name</b>
Ethyol	Amifostine
Fabrazyme	Agalsidase
Reopro	Abciximab
Visudyne	Verteporfin
There are multiple brand names for this drug	sodium hyaluronate

### *Complete drug listing effective October 1, 2006*

<b>Brand Name</b>	<b>Chemical Name</b>
Aralast	alpha 1 proteinase inhibitor
Aranesp	darbepoetin alfa
Aredia	pamidronate
Avastin	bevacizumab
Botox	botulinum toxin
Bravelle	urofollitropin
Camptosar	irinotecan
Coly-Mycin M	colistimethate
Epogen	epoetin alfa
Fertinex	urofollitropin
Flolan	epoprostenol
Gemzar	gemcitabine
Genotropin	somatropin
Gliadel Wafer	carmustine polifeprosan 20
Herceptin	trastuzumab
Lupron	leuprolide
NovoSeven	coagulation factor viia
Orencia	abatacept
Paraplatin	carboplatin
Procrit	epoetin alfa
Prolastin	alpha 1 proteinase inhibitor
Raptiva	efalizumab
Remicade	infliximab

<b>Brand Name</b>	<b>Chemical Name</b>
Remodulin	treprostinil
Rituxan	rituximab
Somavert	pegvisomant
Supprelin	histrelin
Synagis	palivizumab
Taxol	paclitaxel
Taxotere	docetaxel
Thyrogen	thyrotropin alfa
Vantas	histrelin
Xolair	omalizumab
Zemaira	alpha 1 proteinase inhibitor
Zometa	zoledronic acid
There are multiple brand names for this drug	hemophilia clotting factor viii
There are multiple brand names for this drug	hemophilia clotting factor ix
There are multiple brand names for this drug	immune globulin-intravenous
N/A	17 alpha-hydroxyprogesterone caproate (17P)
There are multiple brand names for this drug	von Willebrand factor complex, human

Synagis (palivizumab) and Xolair (omalizumab) still require the Clinical Guideline and Prescription form.